Premium
P1‐263: Relating PET and CSF Measure of TAU Pathology
Author(s) -
Gordon Brian Andrew,
Friedrichsen Karl A.,
Brier Matthew R.,
Blazey Tyler,
Su Yi,
Christensen Jon,
McConathy Jonathan,
Aldea Patricia,
Holtzman David M.,
Cairns Nigel J.,
Morris John C.,
Fagan Anne M.,
Ances Beau,
Benzinger Tammie LS.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1012
Subject(s) - positron emission tomography , dementia , cerebrospinal fluid , pathology , standardized uptake value , medicine , population , cohort , nuclear medicine , psychology , disease , environmental health
analyses to compare the three participant groups to each other within each PET modality. All results were reported at a FDR corrected threshold p <0.05. Results: Both Flutametamol and PiB showed greater signal throughout grey matter (GM) structures in AD vs. eCN or yCN as expected. (Figure) In all intragroup comparisons (yCN, eCN, and AD), greater white matter (WM) uptake was seen with Flutametamol vs. PiB. In yCN and eCN greater diffuse GM uptake was also seen with Flutametamol vs. PiB (although not as uniform and with a lower T-statistic (5) vs white matter (15)). Greater scalp and parotid uptake was seen in Flutametamol vs. PiB. Greater venous sinus signal was seen with PiB vs Flutametamol. When comparing yCN to eCN for each imaging drug, greater WM uptake was seen in eCN vs yCN. Conclusions: Flutametamol and PiB show similar GM uptake distributions in AD dementia vs CN participants. Differences in WM accumulation between the two amyloid tracers suggest quantitative differences will be apparent when using WM as a reference region. Both imaging drugs demonstrate an age dependent increase in WM binding.